Cell Therapy News

The FDA cleared an investigational new drug application for ALVR109 for the treatment of high-risk adults with COVID-19 infection, according to the agent’s manufacturer.

In this installment of In Practice, Marco L. Davila, MD, PhD, and Rawan G. Faramand, MD, of H. Lee Moffitt Cancer Center and Research Institute in Tampa, discuss the importance of developing a patient-specific management strategy to limit severe toxicities and mortality after chimeric antigen receptor T-cell therapy.

Development of immune effector cell-associated neurotoxicity syndrome did not negatively affect survival outcomes among patients treated with axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma, study results showed.

The FDA cleared an investigational new drug application for a mesenchymal stromal cell therapy to treat radiotherapy-induced xerostomia, also known as dry mouth.

The COVID-19 pandemic has created unprecedented challenges for the scientific community.

Autologous cell-based therapy in patients with acute MI may decrease HF hospitalization, according to the BAMI trial, which was converted to an observational trial due to low patient recruitment.

Kite Pharma has submitted a supplemental biologics license application to the FDA for axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma, according to the agent’s manufacturer.

The Institute for Clinical and Economic Review is taking public comment for its planned assessment of chimeric antigen receptor T-cell therapies for the treatment of multiple myeloma.

Leukemia Research Foundation awarded $1.3 million in grants to support new investigators who are conducting studies related to blood cancer.

Chimeric antigen receptor T-cell therapy administration cost nearly $33,000 more at academic inpatient hospitals than nonacademic specialty oncology networks, according to study results published in JAMA Network Open.